HPV Vaccination: Current Global Status
Human papillomavirus vaccines have been in use in populations for nearly 10 years. They now have an established record of high efficacy, effectiveness and safety in the prevention of vaccine-type HPV infection and disease, including genital warts and pre-cancers. Their considerable immunogenicity has resulted in trials to study two-dose schedules, which are now approved by WHO and in many countries for use in young adolescents at a spacing of at least 6 months between doses. As of mid 2015, 65 countries have HPV vaccines on their national immunisation schedule, with variable coverage achieved to date.
KeywordsHuman papillomavirus HPV vaccine Immunisation Vaccine coverage
Compliance with Ethics Guidelines
Conflict of Interest
Julia M. L. Brotherton declares to have been an investigator on investigator designed unrestricted epidemiological research grants partially funded through bioCSL but has received no personal financial benefits.
Paul J. N. Bloem declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.•Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. Excellent summary of the impacts of HPV vaccination to date.CrossRefPubMedGoogle Scholar
- 3.Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. March 12, 2014. Available at: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_State ment_HPV_12_Mar_2014.pdf?ua=1
- 5.Nygard M KS, Dillner J et al. Long-term effectiveness and immunogenicity of Gardasil in the Nordic countries. Abstract OC 6–3, Eurogin 2013, Florence, Italy 3–6 November (pg 201 abstract book). 2013.Google Scholar
- 6.Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10.CrossRefPubMedGoogle Scholar
- 7.Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4- year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.CrossRefPubMedGoogle Scholar
- 8.Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer prevention research (Philadelphia). Cancer Prevent Res (Philadelphia, PA). 2009;2(10):868–78.CrossRefGoogle Scholar
- 13.Apter D, Wheeler CM, Paavonen J, Castellsague X, Garland SM, Skinner SR, et al. Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomised, double-blind PATRICIA trial. Clin Vaccin Immunol. 2015;22(4):361–73.CrossRefGoogle Scholar
- 14.Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, et al. Reduced prevalence of vulvar HPV 16/18 infection among women who received the HPV 16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. J Infect Dis. 2014;210(12):1890–9.CrossRefPubMedGoogle Scholar
- 15.Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez- Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ (Clin Res Ed). 2010;341:c3493.CrossRefGoogle Scholar
- 16.Ault KA, Future II, Group S. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–8.CrossRefPubMedGoogle Scholar
- 17.Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.CrossRefPubMedGoogle Scholar
- 20.Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmeron J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213–27.CrossRefPubMedGoogle Scholar
- 21.•Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ (Clin Res ed). 2012;344:e1401. Analysis of trial data suggesting a benefit of vaccination for secondary prevention of new infection and disease in women with previous high grade disease.CrossRefGoogle Scholar
- 24.Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93.CrossRefPubMedGoogle Scholar
- 25.Dunne EF, Naleway A, Smith N, Crane B, Weinmann S, Braxton J, et al. Reduction in HPV vaccine type prevalence among young women screened for cervical cancer in an integrated health care delivery system, United States 2007, 2012–2013. J Infect Dis. 2015.Google Scholar
- 27.Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ (Clin Res Ed). 2013;346:f2032.Google Scholar
- 28.Sando N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study. Acta Dermato-Venereol. 2014;94(3):288–92.CrossRefGoogle Scholar
- 30.Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case–control study nested within a population based screening programme in Australia. BMJ (Clin Res Ed). 2014;348:g1458.Google Scholar
- 35.Cervical screening in Australia 2012–2013. Australian Institute of Health and Welfare. Cancer Series No. 93 Cat. No. CAN 91.Google Scholar
- 38.Brown D, Muller M, Sehr P, Pawlita M, Seitz H, Rubio I, et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine. 2014;32(44):5880–7.CrossRefPubMedGoogle Scholar
- 40.Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV- 6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Human Vaccines. 2011;7:1343–58.PubMedCentralCrossRefPubMedGoogle Scholar
- 42.Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vacc Immunother. 2014;10(5).Google Scholar
- 43.•Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. Trial demonstrating equivalent immunogenicity of two doses of quadrivalent HPV vaccine in young adolescents.CrossRefPubMedGoogle Scholar
- 44.Human papillomavirus vaccines: WHO position paper, October 2014, WER. Available at: http://www.who.int/wer/2014/wer8943.pdf?ua=1
- 45.•Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study. Hum Vaccin Immunother. 2015; 15:0. Study showing sustained immunogenicity of two doses of bivalent HPV vaccine in adolescents and predicting durable protection.Google Scholar
- 46.•Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV- 16/18 AS04 adjuvanted vaccine: combined analysis of data from the Cosa Rica vaccine trial and the PATRICIA Trial. Lancet Oncol. 2015;16(7):775–86. Analysis suggesting equivalent efficacy to three doses from one or two doses of bivalent HPV vaccine.CrossRefPubMedGoogle Scholar
- 49.Brotherton JML, Malloy M, Budd A, Saville M, Drennan K, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Research. in press, 2015.Google Scholar
- 51.•Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9- valent HPV vaccine against infection and intraepithelial neoplasia in women. N Eng J Med. 2015;372(8):711–23. RCT analysis for the nine valent HPV vaccine showing equivalent immunogenicity as quadrivalent vaccine against types 6/11/16/18 and high efficacy against types 31/33/45/52/58.CrossRefGoogle Scholar
- 57.•Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clin Res Ed). 2013;347:f5906. Robust whole of population safety study establishing no increase in autoimmune, neurological or thromboembolic disease in HPV vaccine recipients.Google Scholar
- 67.Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An overview of quadrivalent human papillomavirus vaccine safety—2006 to 2015. Pediat Infect Dis. 2015.Google Scholar
- 68.Gardasil (quadrivalent human papillomavirus vaccine), update 2. Australian Government, Department of Health, Therapeutic Goods Administration. Available at: https://www.tga.gov.au/alert/gardasil-quadrivalent-human-papillomavirus-vaccine-update-2.
- 72.EMA to further clarify safety profile of human papillomavirus (HPV) vaccines. Press release, European Medicines Agency, Science Medicines Health, 13 July, 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/07/WC500189481.pdf.
- 74.WHO/UNICEF joint reporting form, 1 July 2015. Available from: http://www.who.int/immunization/monitoring_surveillance/data/en/.
- 75.Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Washington DC, March 20, 2014 (PAHO/WHO) Available at: http://www.paho.org/hq/index.php?option=com_content&view=article& id=9394:el-80-de-las-ninas-adolescentes-de-las-americas-tendra-acceso- a-la-vacuna-contra-el-vph-tras-haberse-introducido-en-brasil- &catid=740:news-press-releases&Itemid=1926&lang=en 2014.
- 88.Verger P, Fressard L, Collange F, Gautier A, Jestin C, Launay O, et al. Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France. EBioMedicine, in press. 2015.Google Scholar
- 89.WHO (2014) Considerations regarding consent in vaccinating children and adolescents between 6–17 years old. Available at: http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CB0QFjAAahUKEwjC5-2FxvDGAhWDG6YKHdx-Bm8&url=http%3A%2F%2Fwww.who.int%2Fimmunization%2Fprogrammes_systems%2Fpolicies_strategies%2Fconsent_note_en.pdf&ei=MH-wVcKPBYO3mAXc_Zn4Bg&usg=AFQjCNEwRluf1NJ7DKWnb6wL5gw-jDddWQ&sig2=iFyYo16UYKqT36csUH6JXA&bvm=bv.98476267,d.dGY